Profile data is unavailable for this security.
About the company
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
- Revenue in USD (TTM)103.27m
- Net income in USD-64.24m
- Incorporated2007
- Employees459.00
- LocationLifecore Biomedical Inc3515 Lyman BoulevardCHASKA 55318United StatesUSA
- Phone+1 (952) 368-4300
- Fax+1 (302) 636-5454
- Websitehttps://www.lifecore.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alimera Sciences Inc | 80.75m | -21.39m | 167.60m | 159.00 | -- | 3.63 | -- | 2.08 | -2.16 | -2.16 | 3.17 | 0.8819 | 0.8235 | 6.22 | 2.98 | 507,886.80 | -20.53 | -19.08 | -29.94 | -27.37 | 86.58 | 86.80 | -24.93 | -19.55 | 2.31 | -0.1919 | 0.5835 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
| Vaxart Inc | 8.89m | -81.74m | 169.55m | 109.00 | -- | 3.04 | -- | 19.08 | -0.5431 | -0.5431 | 0.059 | 0.3155 | 0.0813 | -- | 21.67 | 81,513.76 | -74.81 | -49.60 | -86.63 | -54.86 | -- | -- | -920.00 | -1,398.00 | -- | -- | 0.0705 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 171.26m | 135.00 | -- | 6.97 | -- | 9.71 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.32m | 171.26m | 22.00 | -- | 3.46 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Kodiak Sciences Inc | 0.00 | -232.75m | 173.37m | 107.00 | -- | 0.7186 | -- | -- | -4.44 | -4.44 | 0.00 | 4.59 | 0.00 | -- | -- | 0.00 | -43.30 | -31.73 | -47.44 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 179.31m | 459.00 | -- | -- | -- | 1.74 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 180.04m | 3.00 | -- | 26.81 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 181.22m | 84.00 | -- | -- | -- | 51.78 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Outlook Therapeutics Inc | 0.00 | -51.50m | 181.26m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| OptiNose Inc | 74.02m | -30.75m | 182.50m | 132.00 | -- | -- | -- | 2.47 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 182.99m | 1.00 | -- | 60.66 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 44.95m | 2.84m | 190.78m | 36.00 | 192.51 | 63.31 | 67.08 | 4.24 | 0.0366 | 0.0366 | 1.62 | 0.1112 | 0.9878 | 1.15 | 7.52 | -- | 6.25 | -73.43 | 7.37 | -84.32 | 96.19 | -- | 6.33 | -383.28 | 6.72 | 1.84 | 0.9087 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| P3 Health Partners Inc | 1.35bn | -67.27m | 191.09m | 400.00 | -- | 0.4924 | -- | 0.1413 | -0.5855 | -0.5855 | 11.86 | 1.23 | 1.57 | -- | 11.40 | 3,381,965.00 | -21.31 | -- | -90.11 | -- | 1.59 | 0.1781 | -13.57 | -56.93 | -- | -10.05 | 0.2368 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
Data as of May 20 2024. Currency figures normalised to Lifecore Biomedical Inc's reporting currency: US Dollar USD
56.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wynnefield Capital, Inc.as of 31 Mar 2024 | 4.92m | 16.12% |
| Legion Partners Asset Management LLCas of 31 Mar 2024 | 2.95m | 9.66% |
| Greenhaven Road Investment Management LPas of 31 Mar 2024 | 2.14m | 7.02% |
| 22NW LPas of 31 Mar 2024 | 1.76m | 5.75% |
| 325 Capital LLCas of 31 Mar 2024 | 1.34m | 4.39% |
| Cove Street Capital LLCas of 31 Mar 2024 | 1.28m | 4.20% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.17m | 3.84% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 627.70k | 2.06% |
| Visionary Wealth Advisors LLCas of 31 Mar 2024 | 496.78k | 1.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 460.45k | 1.51% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
